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Background: Many markers have been proposed for CVD risk assessment in dialysis population. Apelin is a peptide
that has roles in cardiovascular functions and volume regulation namely vasodilation, decreased blood pressure
(BP), positive inotropic effect and inhibition of antidiuretic hormone release. The aim of this study was to examine
relationship of apelin levels with echocardiographic findings and laboratory parameters related with cardiovascular
function and bone mineral metabolism among peritoneal dialysis (PD) patients.
Methods: This is a cross-sectional study in which chronic PD patients aged between 18 and 80 without active
cardiac, infectious or malignant diseases and hypervolemia have been included. Apelin-36 levels and
echocardiographic findings were recorded as well as clinical and laboratory data.
Results: Of the 53 patients, the mean age and female/male ratio was 52.8 ± 15.3 years and 30/23, respectively.
Mean apelin level was 1.45 ± 0.37 ng/ml. Gender, drugs (renin-angiotensin-aldosteron inhibitors, statins), presence
of left ventricular hypertrophy, diabetes mellitus, hypertension, hyperlipidemia and significant residual renal function
did not affect apelin-36 levels. Apelin-36 was correlated negatively with age and left atrium diameter; and positively
with diastolic BP, ejection fraction (EF), total cholesterol, LDL-cholesterol, HDL-cholesterol, parathyroid hormone and
alkaline phosphatase (ALP) levels. Diastolic BP, LDL-cholesterol, ALP and EF were found to be the independent
determinants of apelin-36 levels with linear regression analysis.
Conclusions: Apelinergic system has important roles in volume regulation, cardiovascular functions, lipid
metabolism and bone mineral disorders in PD patients. Prospective studies with large population are required.
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The mortality rate of patients with end stage renal di-
sease (ESRD) is markedly elevated compared with the
general population; and the major reason of this finding
is cardiovascular disease (CVD) which is responsible for
40-60% of these deaths [1]. Left ventricular hypertrophy
(LVH), that is more prevalent in peritoneal dialysis (PD)
than hemodialysis (HD) population, is a strong indicator
of cardiomyopathy and an important reason for sudden
cardiac death [1-3]. About 40% of patients with ESRD* Correspondence: drmeltemgursu@gmail.com
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reproduction in any medium, provided the orare diagnosed to have congestive heart failure which re-
sults mostly from diastolic dysfunction and circulatory
congestion [4]. Besides LVH, accelerated atherosclerosis,
arteriosclerosis, and vascular remodeling are thought to
cause increased CVD rate [1].
Peritoneal dialysis patients are different than HD pa-
tients in terms of CVD risk. About one third of PD pa-
tients are hypervolemic that is found to be related with
increased mortality rate [5]. Moreover, traditional risk
factors like hyperglycemia, hyperlipidemia and obesity
are more prevalent in PD population [6].
Many markers have been proposed for CVD risk as-
sessment in dialysis population. Apelin is a peptide of
which the pathophysiological effects have been elucidatedl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dogenous ligand of APJ receptor which is a G protein
coupled membrane receptor [7,8]. APJ receptor has close
homology with angiotensin-1 (AT-1) receptor although
apelin and angiotensin do not share their receptors [9].
APJ receptors have been detected in endothelial cells of
small intramyocardial, renal, pulmonary and bronchial
vessels, coronary arteries, endocardial cells and vascular
smooth muscle cells [10]. Preproapelin is located widely in
human body mainly in central nervous system, placenta,
kidneys, heart, lungs, adipose tissue and mammarian
glands [11]. It has been claimed to be secreted by en-
dothelial cells in conjunction with other vasoactive
mediators [9].
Apelin is thought to play roles in cardiovascular
functions and volume regulation like vasodilation and
decreased blood pressure [12]; vasoconstriction in the
presence of dysfunctional endothelium [13]; positive ino-
tropic effects [14]; inhibition of antidiuretic hormone
(ADH) release [15]; dilation of afferent and efferent ar-
terioles, and vasoconstrictive effects on smooth muscle
cells [16]. Apelinergic system is up regulated in early
stages of heart failure possibly as a compensatory me-
chanism, and down regulated in later stages [17,18]. It is
well known that bone mineral disorders and the related
vascular calcification plays an important role in the
pathogenesis of CVD in uremic patients. Studies have
shown that apelin and its receptor, present in osteo-
blasts, suppress apoptosis and increase proliferation of
osteoblasts [19,20]. Another study proposed that apelin
is protective against vascular calcification through inhib-
ition of osteoblastic differentiation of vascular smooth
muscle cells [21].
The knowledge about the role of apelin in pathophysi-
ology of cardiovascular disease is not sufficient enough
in uremic patients, especially in PD patients. The aim of
this study was to examine relationship of apelin-36 levels
with echocardiographic findings and laboratory parame-
ters which may be related with cardiovascular function
and bone mineral metabolism among PD patients.
Methods
Among 69 chronic PD patients followed in our PD unit;
those aged between 18 and 80, with dialysis duration
more than three months and without active cardiac
(acute coronary syndrome, idiopathic dilated cardiomyo-
pathy, infective endocarditis, decompensated heart failure,
valvular heart disease, congenital heart diseases, atrial fib-
rillation and other arrythmias, pacemaker need, pericardial
diseases), infectious or malignant disease and hypervole-
mia (clinically prominent dypnea, edema, pulmonary con-
gestion findings, ascites, and cardiomegaly on radiograph)
and those who gave informed consent have been included
in the present study. Ethical approval was not gained dueto the design of the study that does not necessitate inva-
sive procedures or drug use.
Age, gender, body mass index (BMI), systolic, diastolic
and mean blood pressures, primary kidney disease, dialysis
duration, dialysis modality (CAPD-continuous ambulatory
peritoneal dialysis-, CCPD-continuous cyclic peritoneal
dialysis-, APD-automated peritoneal dialysis), Kt/V values,
mean daily urine volume, residual glomerular filtration
rates, residual and total creatinine clearances and all medi-
cations were recorded. The comorbidities of the patients
including hypertension, hyperlipidemia, ischemic heart
disease and diabetes mellitus were recorded. Pateints
who were dignosed to have hypertension before, and those
with blood pressure more than 140/90 mmHg in at least
two measurements were regarded to have hypertension.
Patients on antidiabetic treatment with previous diagnosis
of diabetes mellitus; or those with fasting blood glucose
above 126 mg/dl; or blood glucose level above 200 mg/dl
at any time or blood glucose level above 200 mg/dl on
second hour measurement of oral glucose tolerance test
were recorded as diabetic. The diadnosis of hyperli-
pidemia was put according to the criteria of National
Cholesterol Education Program-Adult Treatment Panel
(NCEP-ATP) III regarding the age and other risk factors
of the patients. Ischemic heart disease was diagnosed in
patients with previous medical history (previous acute cor-
onary syndrome, coronary artery by-pass surgery, history
of baloon angioplasty or stent implantation, coronary le-
sions on coronary angiography, etc.), those with typical
symptoms of coronary artery disease (angina pectoris or
angina equivalents), patients with typical findings on elec-
trocardiography, echocardiography, stress tests or coron-
ary angiography.Blood samples for hematological and
biochemical measurements were obtained after 12-hour
fasting with their abdomen left empty the night before.
Serum glucose, urea, creatinine, uric acid, total choles-
terol, LDL-cholesterol, HDL-cholesterol, triglyceride, so-
dium, calcium, phosphorus, alkaline phosphatase (ALP),
total protein, albumin, aspartate aminotransferase (AST)
and alanine aminotransferase (ALT), parathyroid hormone
(PTH), high sensitive C reactive protein (hsCRP), ferritin,
hemoglobin and hematocrite levels were measured by
appropriate methods.
Measurement of apelin levels
Blood samples of 4 ml were drawn to tubes coated with
ethylen diamin tetra acetic acid (EDTA). The samples
were centrifuged at 1600 g for 15 minutes, and the plas-
ma samples obtained were kept at −80°C for one month.
The samples and the reactives were turned to room tem-
perature prior to study. Plasma apelin-36 levels were
studied by competitive enzyme immunoassay method
using Phoenix Pharmaceuticals, Inc, Human Apelin-36
Enzyme Immunoassay kit (Range: 0-100 ng/ml). The





Systolic blood pressure (mmHg) 128±21
Diastolic blood pressure (mmHg) 80±10
Mean blood pressure (mmHg) 96±14
PD duration (months) 41.7±24.9
Primary kidney disease n (%)
Hypertension 8 (15)
Unknown 14 (26)
Diabetes mellitus 14 (26)
Glomerulonephritis 6 (11)
ADPKD 3 (6)
Postrenal reasons 8 (16)
Co-morbidities n (%)
Hypertension 41 (77)
Diabetes mellitus 15 (17)
Hyperlipidemia 21 (40)
Ischemic heart disease 9 (28)
BMI; body mass index, ADPKD; autosomal dominant polycystic kidney disease.











Total protein (g/dl) 6.5±0.8
Albumin (g/dl) 3.8±0.4










hsCRP (mg/dl) 2.0 ±4.3
HDL; high density lipoprotein, LDL; low density lipoprotein, AST; aspartate
aminotransferase, ALT; alanine aminotransferase.
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calibration curves obtained from study of samples and
standards with known levels.
General Electric VIVID-7 machine was used for echo-
cardiographic examination by the same physician. Dia-
meters of cardiac chambers were measured by M-mode
ultrasonography. Ejection fraction (EF) was calculated by
modified Simpson method. Left ventricular mass (LVM)
was calculated by Devereux formula and left ventricular
mass index (LVMI) was found by dividing LVM by
BSA. Left ventricular hypertrophy was defined as LVMI
above 110 gr/m2 and 134 gr/m2 for females and males,
respectively [22].
Statistical analysis was conducted by SPSS (Statistical
Package for Social Sciences) 15 for Windows standard
version. Numerical values were expressed as mean ±
standard deviation (SD). Intergroup comparisons were
made by paired Student t-test and Mann Whitney U test
when necessary. For nonnumerical parameters, for 2×2
contingency tables chi-square test and Fisher’s exact test
when appropriate. Correlation analysis was conducted
with Pearson test for parametric variables and Spearman’s
rho correlation test for nonparametric variables. Linear re-
gression analysis was performed by enter method with
variables found to be related with apelin-36 levels in uni-
variate analysis.
Results
Fifty three patients were included in the study. Mean age
and female/male ratio was 52.8 ± 15.3 years and 30/23,
respectively. Dialysis modality was CAPD in 33 (62.3%),
APD in 17 (32.1%) and CCPD in 3 (5.7%) patients. Demo-
graphic and clinical data are presented in Table 1. The
most common etiology of ESRD was diabetes mellitus and
the most common co-morbidity was hypertension (77%).
The biochemical and hematological data are presen-
ted in Table 2. Mean plasma apelin-36 level was 1.45 ±
0.37 ng/ml. There was no difference between levels found
in males and females (p = 0.15). Apelin-36 levels were si-
milar in patients taking and not taking angiotensin con-
verting enzyme inhibitors (p = 0.35), angiotensin receptor
blockers (p = 0.31), renin angiotensin aldosteron system
blockers in general (p = 0.84) and statins (p = 0.64).
Echocardiographic findings are presented in Table 3.
Patients with (n = 34) and without (n = 19) LVH had
similar apelin-36 levels (1.41 ± 0.28 ng/ml vs. 1.53 ±
0.49 ng/ml, p = 0.29). Similarly apelin-36 levels were statis-
tically not different in patients with or without ischemic
heart disease (1.28 ± 0.29 ng/ml vs. 1.49 ± 0.38 ng/ml,
p = 0.11). Presence of diabetes mellitus (1.52 ± 0.42 ng/ml
vs. 1.43 ± 0.35 ng/ml; p > 0.05), hypertension (1.45 ±
0.51 ng/ml vs. 1.47 ± 0.15 ng/ml, p > 0.05) and hyperlipi-
demia (1.37 ± 0.77 ng/ml vs. 1.50 ± 0.38 ng/ml, p > 0.05)
did not differ apelin-36 levels also.
Table 3 Echocardiographic findings of the study group
Mean±SD
Left atrium diameter (cm) 3.58±0.56
Left ventricle end diastolic diameter (cm) 4.63±0.59
Left ventricle end systolic diameter (cm) 3.01±0.58
Ejection fraction (%) 62.06±8.9
Interventricular septum thickness (cm) 1.24±0.22
Right ventricle diameter (cm) 2.53±0.27
Aorta diameter (cm) 3.21±0.32
Pulmonary artery diameter (cm) 2.09±0.24
Left ventricle mass (gram) 246.8±82.6
Left ventricle mass index (gr/m2) 140.8±42.9




Constant −0.586 0.447 −1.311 0.196
Diastolic blood pressure 0.011 0.004 0.334 3.148 0.003
Alkaline phosphatase 0.001 0.000 0.487 4.630 0.000
LDL-cholesterol 0.003 0.001 0.256 2.438 0.019
Ejection fraction 0.011 0.004 0.265 2.499 0.016
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820 ± 790 ml and 3.4 ± 3.3 ml/min/1.73 m2, respect-
ively. Patients with significant residual renal function
meaning GFR ≥ 2 ml/min/1.73 m2 (n = 32) had similar
apelin-36 levels with those without significant residual
renal function (1.44 ± 0.38 ng/ml vs. 1.47 ± 0.36 ng/ml,
p = 0.83). All patients met the criteria for dialysis ad-
equacy with mean total, dialysate and renal Kt/V values
of 2.51 ± 0.66, 1.80 ± 0.47 and 0.71 ± 0.71 respectively.
The mean total creatinine clearance was 79.1 ± 29.2 ml/
min/1.73 m2.
Among the demographic parameters, only age was
negatively correlated with apelin-36 levels (r = −0.277,
p = 0.044). Apelin-36 was positively correlated with
diastolic blood pressure (r = 0.37, p = 0.006), total choles-
terol (r = 0.271, p = 0.050), LDL-cholesterol (r = 0.313,
p = 0.023), HDL-cholesterol (r = 0.317, p = 0.021), PTH
(r = 0.322, p = 0.019) and ALP (r = 0.510, p <0.0001)
levels. There was no correlation of apelin-36 with hema-
tological variables, hsCRP, Kt/V, creatinine clearance and
residual renal function. Among the echocardiographic pa-
rameters; apelin-36 was positively correlated with EF
(r = 0.298, p = 0.030), and negatively with left atrium dia-
meter (r = −0.288, p = 0.036).
Linear regression model was applied with parameters
found to be correlated with apelin-36 in univariate ana-
lysis besides gender, PD modality and primary kidney
disease. Diastolic blood pressure, LDL-cholesterol, ALP
and EF were found to be the independent determinants
of apelin-36 levels (Table 4). When this analysis was re-
peated dividing the patients into two groups according
to the presence of hypertension; diastolic blood pres-
sure (B = 0.001, beta = 0.42, p = 0.002), LDL-cholesterol
(B = 0.003, beta = 0.35, p = 0.021) and EF (B = 0.01,
beta = 0.27, p = 0.049) remained as the determinants in
hypertensive group; while ALP (B = 0.001, beta = 1.08,
p = 0.009) was the only one in patients without hyper-
tension (Figure 1).Discussion
It is very difficult to mention a standard normal level of
apelin due to the presence of various forms of apelin
(apelin-12, apelin-13, apelin-18, apelin-36) in the circula-
tion. Besides this factor; different kits for measurement
and the cross reaction between the types of apelin lead
to various levels mentioned in the literature. Foldes et al.
reported normal apelin levels as 89.8 ± 5.3 pg/ml [23].
Malyszko et al. reported that level as 84.0 ± 9.26 pg/ml
in the general population and 49.16 ± 22.19 pg/ml in HD
patients using the same assay (apelin-36 radioimmuno-
assay using commercially available kit from Phoenix Phar-
maceuticals Inc., USA) with Foldes et al. [24]. Codognotta
et al. found normal levels of apelin in the general popula-
tion as 100 pg/ml [25]. Mean apelin-12 level was reported
as 304 pg/ml in the normal population [26], 1.14 ng/ml in
patients with stable angina pectoris [27]. El-Mesallamy
[28] reported normal level of apelin-12 in the healthy
population as 1.11 ng/ml.
The literature data about apelin levels in patients with
ESRD is limited, so there is no cut-off value for it. But
studies reported lower values in dialysis patients com-
pared with the general population [24]. Apelin level was
found to be lower in uremic patients with dilated cardio-
myopathy than in nonuremic counterparts; which leads
to the speculation that uremia decreases apelin levels ir-
respective of the degree of heart failure [25]. There is no
data about the clearance of apelin during HD or PD in
the literature. But it has been speculated that due to its
molecular weight it is expected to be filtered through
the glomerulus but not through low-flux hemodialysis
membranes; so dialysis clearance can not be the reason
of lower levels in HD patients [25]. We think that apelin
may be cleared from the circulation in PD patients due
to larger pore size of the peritoneal membrane.
The increased rate of CVD in uremic population is
well known. One of the factors increasing cardiovascular
risk in PD population is hypervolemia. In our study we
found relationships between apelin-36 levels and dia-
stolic blood pressure, left atrium diameter and EF all of
which are related with volume status of the patients. Al-
though patients with evident hypervolemia were excluded
from the study; these relations which are present espe-
cially in the hypertensive group mark the relationship of
Figure 1 The graphical presentation of parameters found in multivariated analysis to be correlated with apelin-36 levels in patients
with (a,b,c) and without (d) hypertension. dbp: Diastolic blood pressure; ldl: LDL cholesterol; ef: Ejection fraction; alp: Alkaline phosphatase.
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may be an evidence for its positive inotropic action re-
ported in previous studies [14,29,30]. Malyszko et al. [24]
reported correlation between apelin levels and left ven-
tricle end diastolic and end systolic diameters, biatrial di-
ameters, right ventricle diameter, left ventricle posterior
wall thickness and aorta diameter which are all indirect
markers for volume status in HD patients.
We did not investigate directly the relationship be-
tween apelin-36 and body fluid status. But, when results
of our study are considered together with literature data;
it may be speculated that hypervolemia that is prevalent
in dialysis population causes elevations in apelin levels
to maintain compensatory diuresis, increased cardiac
contractility and vasodilation. But there is not enough
data to accept this theory as a fact.
The physiological effects of apelin mentioned before
(positive inotropism, vasodilation, decreased blood pres-
sure, and diuresis through effects on central nervous
system) seem to antagonize deleterious effects of renin-angiotensin-aldosteron system (RAAS) [31]. It is clear that
there is need for large scaled studies about the patho-
physiological and therapeutic role of apelin in both uremic
and non-uremic population.
Malyszko et al. [24] found apelin levels lower in HD
patients with ischemic heart disease than those without
ischemic heart disease. The levels were lower in patients
with ischemic heart disease in our study also, but the
difference was not statistically significant. This may be
related with the small number of patients.
The strong correlation of apelin-36 with LDL and
HDL-cholesterol is an interesting finding. Although ape-
lin is secreted also from adipose tissue, this is not suf-
ficient to explain the relationship. Malyszko et al. [24]
found negative correlation between apelin and total
cholesterol, LDL-cholesterol and triglyceride levels in
HD patients. This difference from our study may be re-
lated with metabolic abnormalities like hyperglycemia,
dyslipidemia and obesity that are more common in PD
patients due to the glucose content of PD solutions.
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apelin levels were lower in patients with high LDL-
cholesterol in non-uremic population; and lowering LDL-
cholesterol with life style changes and/or statins resulted
in an increase in apelin levels. These different results
between uremic and nonuremic population may be
regarded as a clue for different lipid profile of uremic
patients.
Another effect of apelin is diuresis resulting from in-
hibition of ADH release. Hus-Citharel et al. [16] re-
ported significant diuresis after infusion of apelin-17 to
rats. Lack of correlation between apelin-36 levels and
daily urine output in our study may be due to blunted
diuretic effect of apelin-36 in patients with renal failure
who are supposed not to respond to decreased ADH
levels.
It has been shown by studies that there may be a rela-
tionship between apelin levels and inflammation [32].
Malyszko et al. reported apelin level as correlated with
intracellular adhesion molecule, adiponectin and the pre-
sence of coronary arery disease in patients with trans-
planted kidneys [33]. El-Shehaby et al. found a negative
correlation of apelin levels with interleukin-6 and hsCRP
levels [34]. Although the aim of our study was not to
investigate apelin-inflammation relation; there was no
correlation with hsCRP levels.
Apelin has been found as an independent predictor of
bone mineral density in post- menopausal women [35].
Other studies showed apelin expression in osteoblasts,
and reported that apelin increases osteoblast prolifera-
tion while suppressing apoptosis of these cells [19,20]. In
another study, apelin has been reported to decrease os-
teoblastic differentiation of vascular smooth muscle cells
and vascular calcification which are important in the
pathogenesis of CVD in uremia [21]. The significant cor-
relation of apelin-36 with ALP and PTH detected in our
study gains meaning considering these literature data.
Apelinergic system may be supposed to be active in the
pathogenesis of bone mineral metabolism disorders in
uremic patients.
Conclusion
Apelinergic system has important roles in volume re-
gulation, cardiovascular functions, lipid metabolism and
bone mineral disorders in PD patients. Prospective studies
with large population are required.
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